A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs AK 01 (Primary)
- Indications Breast cancer; Head and neck cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AurKa Pharma; Eli Lilly
- 20 Aug 2018 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 20 Aug 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
- 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.